Skip to main content
Journal cover image

Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

Publication ,  Journal Article
Thompson, AJ; Santoro, R; Piazzolla, V; Clark, PJ; Naggie, S; Tillmann, HL; Patel, K; Muir, AJ; Shianna, KV; Mottola, L; Petruzzellis, D ...
Published in: Hepatology
February 2011

UNLABELLED: Two functional variants in the inosine triphosphatase (ITPA) gene causing inosine triphosphatase (ITPase) deficiency protect against ribavirin (RBV)-induced hemolytic anemia and the need for RBV dose reduction in patients with genotype 1 hepatitis C virus (HCV). No data are available for genotype 2/3 HCV. We evaluated the association between the casual ITPA variants and on-treatment anemia in a well-characterized cohort of genotype 2/3 patients treated with variable-duration pegylated interferon alfa-2b (PEG-IFN-α2b) and RBV. Two hundred thirty-eight Caucasian patients were included in this retrospective study [185 (78%) with genotype 2 and 53 (22%) with genotype 3]. Patients were treated with PEG-IFN-α2b plus weight-based RBV (1000/1200 mg) for 12 (n = 109) or 24 weeks (n = 129). The ITPA polymorphisms rs1127354 and rs7270101 were genotyped, and an ITPase deficiency variable was defined that combined both ITPA variants according to their effect on ITPase activity. The primary endpoint was hemoglobin (Hb) reduction in week 4. We also considered Hb reduction over the course of therapy, the need for RBV dose modification, and the rate of sustained virological response (SVR). The ITPA variants were strongly and independently associated with protection from week 4 anemia (P = 10(-6) for rs1127354 and P = 10(-7) for rs7270101). Combining the variants into the ITPase deficiency variable increased the strength of association (P = 10(-11) ). ITPase deficiency protected against anemia throughout treatment. ITPase deficiency was associated with a delayed time to an Hb level < 10 g/dL (hazard ratio = 0.25, 95% confidence interval = 0.08-0.84, P = 0.025) but not with the rate of RBV dose modification (required per protocol at Hb < 9.5 g/dL). There was no association between the ITPA variants and SVR. CONCLUSION: Two ITPA variants were strongly associated with protection against treatment-related anemia in patients with genotype 2/3 HCV, but they did not decrease the need for RBV dose reduction or increase the rate of SVR.

Duke Scholars

Published In

Hepatology

DOI

EISSN

1527-3350

Publication Date

February 2011

Volume

53

Issue

2

Start / End Page

389 / 395

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Risk Factors
  • Ribavirin
  • Retrospective Studies
  • Recombinant Proteins
  • Pyrophosphatases
  • Polymorphism, Genetic
  • Polyethylene Glycols
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Thompson, A. J., Santoro, R., Piazzolla, V., Clark, P. J., Naggie, S., Tillmann, H. L., … Mangia, A. (2011). Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology, 53(2), 389–395. https://doi.org/10.1002/hep.24068
Thompson, Alexander J., Rosanna Santoro, Valeria Piazzolla, Paul J. Clark, Susanna Naggie, Hans L. Tillmann, Keyur Patel, et al. “Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.Hepatology 53, no. 2 (February 2011): 389–95. https://doi.org/10.1002/hep.24068.
Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, et al. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology. 2011 Feb;53(2):389–95.
Thompson, Alexander J., et al. “Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.Hepatology, vol. 53, no. 2, Feb. 2011, pp. 389–95. Pubmed, doi:10.1002/hep.24068.
Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, Patel K, Muir AJ, Shianna KV, Mottola L, Petruzzellis D, Romano M, Sogari F, Facciorusso D, Goldstein DB, McHutchison JG, Mangia A. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology. 2011 Feb;53(2):389–395.
Journal cover image

Published In

Hepatology

DOI

EISSN

1527-3350

Publication Date

February 2011

Volume

53

Issue

2

Start / End Page

389 / 395

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Risk Factors
  • Ribavirin
  • Retrospective Studies
  • Recombinant Proteins
  • Pyrophosphatases
  • Polymorphism, Genetic
  • Polyethylene Glycols
  • Middle Aged
  • Male